CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion

American Journal of Hematology, EarlyView.
Source: American Journal of Hematology - Category: Hematology Authors: Source Type: research

Related Links:

Cytokine release syndrome (CRS) remains to be a major adverse effect of chimeric antigen receptor T (CAR-T) cell therapy in B-cell acute lymphoblastic leukemia (B-ALL) and lymphoma. It was urgent to explore novel strategy for managing severe CRS. We conducted a clinical trial to assess the safety and efficacy of CD19-targeting CAR-T-cells in the treatment of relapsed and chemotherapy-refractory B-ALL and lymphoma. A 10-year-old boy with B-ALL who never achieved minimal residual disease (MRD) negative status after 5 courses of chemotherapy was enrolled into our study and received a total of 3.19×106/kg autologous CD19...
Source: Journal of Immunotherapy - Category: Allergy & Immunology Tags: Clinical Studies Source Type: research
Publication date: Available online 15 October 2018Source: Respiratory Medicine Case ReportsAuthor(s): Atsuki Fukada, Hideki Yasui, Tomoaki Uto, Shioto Suzuki, Jun Sato, Shiro Imokawa, Takafumi SudaAbstractAn 85-year-old man who did not have any hematological or respiratory disorders was transferred to our hospital because of progressive dyspnea. Computed tomography (CT) findings showed ground-glass opacities with a centrilobular distribution and centrilobular micronodules with a “tree-in-bud” pattern. A biopsy of the lungs showed lymphocytic infiltrations in the parenchyma and these were positive for B cell mar...
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
Conditions:   Relapsed/Refractory Chronic Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Leukemia Interventions:   Drug: Ibrutinib;   Drug: Venetoclax Sponsor:   Swiss Group for Clinical Cancer Research Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 16 October 2018Source: Leukemia Research ReportsAuthor(s): Lindsey Clarke, Raju SR Adduri, Paul Smyth, Fiona Quinn, Michael Jeffers, Barbara Dunne, John O'Leary, Susan McKiernan, Elisabeth Vandenberghe, Saumyadipta Pyne, Murali Dharan Bashyam, Orla Sheils, Richard Flavin
Source: Leukemia Research Reports - Category: Hematology Source Type: research
Journal Name: Journal of Pediatric Endocrinology and Metabolism Issue: Ahead of print
Source: Journal of Pediatric Endocrinology and Metabolism - Category: Endocrinology Source Type: research
Brooke Evans, from Redditch in Worcestershire, has started work as a haematology nurse at Queen's Hospital in Birmingham, where she had chemo in 2013.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Publication date: Available online 16 October 2018Source: Cancer GeneticsAuthor(s): Kathy Chun, Gail D. Wenger, Alka Chaubey, D.P. Dash, Rashmi Kanagal-Shamanna, Sibel Kanturci, Ravindra Kolhe, Daniel L. Van Dyke, Lu Wang, Daynna J. Wolff, Patricia M. MironAbstractThe prognostic role of cytogenetic analysis is well-established in B-cell chronic lymphocytic leukemia (CLL). Approximately 80% of patients have a cytogenetic aberration. Interphase FISH panels have been the gold standard for cytogenetic evaluation, but conventional cytogenetics allows detection of additional abnormalities, including translocations, complex karyo...
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research
We report a relapsed and refractory Multiple Myeloma (RRMM) and AL Amyloidosis patient responding to elotuzumab/lenalidomide/dexamethasone (ERD). A 51-year-old woman presented with a right mandibular mass with positive Congo-red staining, clonal kappa free-light chains (κFLC) and plasma cell proliferation. Workup was consistent with κFLC amyloidosis and MM with nephrotic range proteinuria. After progression on several lines of therapy, she has near complete reversal of proteinuria while being maintained on ERD. This regimen should be tested in patients with AL Amyloidosis.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Authors: Wu R, Yang H, Wan J, Deng X, Chen L, Hao S, Ma L Abstract Leukemia and lymphoma are common hematological malignancies in children and young adults, which pose a tremendous threat to the survival of these young patients worldwide, despite availability of various effective treatments. The Hippo pathway is a novel‑signaling pathway that regulates organ size, cell proliferation, apoptosis and tumorigenesis. The chief component of this pathway is the transducer yes‑associated protein (YAP) which is over‑expressed in numerous categories of tumors. However, little is known about the effect of YAP in hematol...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
In conclusion, miR‑339‑5p may serve its antiproliferative role in AML by directly targeting SOX4, which suggests that miR‑339‑5p may be considered an effective novel therapeutic target for treating patients with such an aggressive haematological malignancy. PMID: 30320397 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
More News: Hematology | Leukemia